Thalidomide therapy for inflammatory dermatoses.
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000328:Adult; D000818:Animals; D055598:Chemical Phenomena; D002621:Chemistry; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007249:Inflammation / Q000188:drug therapy*; D007918:Leprosy / Q000188:drug therapy; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy; D008297:Male; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011536:Prurigo / Q000188:drug therapy; D011817:Rabbits; D012871:Skin Diseases / Q000188:drug therapy*; D013281:Stomatitis, Aphthous / Q000188:drug therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*
D013792:Thalidomide; C027948:supidimide